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Tubulointerstitial hypoxia plays a critical role in the
pathogenesis of kidney injury, and hypoxia-inducible factor
(HIF)-1 is a master regulator of cellular adaptation to hypoxia.
Aside from oxygen molecules, factors that modify HIF-1
expression and functional operation remain obscure.
Therefore, we sought to identify novel HIF-1-regulating
genes in kidney. A short-hairpin RNA library consisting of
150 hypoxia-inducible genes was derived from a microarray
analysis of the rat renal artery stenosis model screened
for the effect on HIF-1 response. We report that CCAAT/
enhancer-binding protein d (CEBPD), a transcription factor
and inflammatory response gene, is a novel HIF-1 regulator in
kidney. CEBPD was induced in the nuclei of tubular epithelial
cells in both acute and chronic hypoxic kidneys. In turn,
CEBPD induction augmented HIF-1a expression and its
transcriptional activity. Mechanistically, CEBPD directly
bound to the HIF-1a promoter and enhanced its
transcription. Notably, CEBPD was rapidly induced
by inflammatory cytokines, such as IL-1b in a nuclear
factor-jB-dependent manner, which not only increased
HIF-1a expression during hypoxia, but was also indispensable
for the non-hypoxic induction of HIF-1a. Thus our study
provides novel insight into HIF-1 regulation in tubular
epithelial cells and offers a potential hypoxia and
inflammation link relevant in both acute and chronic
kidney diseases.
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Oxygen homeostasis underlies many developmental and
physiological processes, and, its disturbances have key roles
in the pathogenesis of many human diseases, including
kidney disease.1 The kidney requires a complicated vascula-
ture to maintain its structure and function and is thus highly
susceptible to ischemic insults. Indeed, tubulointerstitial
fibrosis is an end-stage feature in chronic kidney disease
(CKD), which is frequently associated with the loss of
peritubular capillary networks reminiscent of hypoxia.2 To
date, there is an increasing body of evidence showing that
tubulointerstitial hypoxia is not only a key player in ischemic
acute kidney injury (AKI) but is also a critical mediator
toward end-stage renal disease in CKD settings.3,4
Hypoxia-inducible factors (HIFs) regulate adaptive re-
sponses to hypoxia at the molecular, cellular, and tissue levels.
HIF is a heterodimeric transcription factor, consisting of an
oxygen-labile a subunit (HIF-1a, HIF-2a, and HIF-3a) and a
constitutively expressed b subunit.5,6 Under normoxia, HIF-a
is hydroxylated by prolyl hydroxylase domain-containing
protein (PHDs) and undergoes proteasomal degradation
assisted by the von Hippel-Lindau (VHL) tumor-suppressor
protein. In hypoxia, the lack of oxygen inhibits PHD activity
and disallows hydroxylation of HIF-a. Stabilized HIF-a
translocates to the nucleus, dimerizes with HIF-1b, and
transactivates its target genes.
In response to hypoxia in kidney, HIF-1a is expressed in
tubular epithelial cells, including proximal and distal tubules,
connecting tubules, and collecting ducts.7 Functional studies
both in vivo and in vitro show that HIF-1 appears to have
protective roles in various acute and chronic kidney injuries.8–15
In addition to its expression control by protein stabiliza-
tion, HIF-1a undergoes transcriptional and translational
regulation, particularly in tumor and inflammatory cells via
the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian
target of rapamycin, nuclear factor (NF)-kB, and extra-
cellular signal–regulated kinase mitogen-activated protein
kinase pathways.16–18 However, it remains unknown whether
the transcriptional and translational control of HIF-1a is
operative in cells of noncancerous tissues, such as renal
tubular cells, and which, if any, genes are responsible for the
HIF-1a upstream signaling.
After taking into account the accumulating knowledge
of HIF-1 on the pathogenesis of both AKI and CKD, we
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designed this study to identify novel HIF-1 regulators
through RNAi library screening.
RESULTS
Identification of HIF-1 regulating genes through short hairpin
RNA (shRNA) library screening
To identify which genes are relevant in HIF-1 regulation,
we created a shRNA library against the top 150 hypoxia-
inducible genes screened from a microarray analysis of
the rat renal artery stenosis (RAS) model, a representative
chronic hypoxic kidney injury model (Supplementary
Table S1 online).19 For the initial screening, the impact of
candidate genes on HIF-1 was evaluated in vitro through a
hypoxia-responsive element (HRE)-driven luciferase (HREluc)
reporter assay (Figure 1a); shRNA transfection against a bona
fide HIF-1-regulating gene would affect HREluc activity. The
hypoxic induction (defined as (luciferase activity in 1% O2)/
(luciferase activity in 21% O2)) was also calculated to exclude
the nonspecific effect. The shRNA-transfected clones showing
hypoxic changes within 50 percentile compared with the
positive control (shRNA anti-HIF-1a) were extracted as hit
clones. Eighteen hit genes proceeded to the second screening.
Stable HeLa cells transfected with shRNA against candi-
date genes were further assessed for the hypoxic induction
of HREluc, HIF-1a protein, and supernatant vascular
endothelial growth factor (VEGF, an endogenous HIF-1
target) expression (Supplementary Figure S1 online). At this
stage, five genes were selected as novel, potential HIF-1-
regulating genes: CCAAT/enhancer-binding protein d
(CEBPD); transforming growth factor-beta-induced factor
(TGIF); paired mesoderm homeobox protein 2A (PHOX2A);
nuclear receptor superfamily 4A member 1 (NR4A1); and
P300/CBP-associated factor (PCAF). Intercellular adhesion
molecule 1 (ICAM1); leucine-rich alpha-2-glycoprotein 1
(LRG1); cytochrome P-450, family 4, subfamily B, polypep-
tide 1 (CYP4B1); and renin (RENIN) were extracted as hit
genes by HREluc activity criteria but did not have positive
effects on HIF-1a or VEGF and were therefore not selected as
candidates (data not shown).
Finally, small interfering RNAs (siRNAs) against these five
candidates were designed and transfected into HeLa cells, and
the above experiments were repeated. PHOX2A was excluded
because of a failure to reduce HIF-1a expression by siRNA,
whereas the remaining four matched the criteria. As a result,
we identified four novel genes––TGIF, NR4A1, PCAF, and
CEBPD––that functionally regulated HIF-1a protein expres-
sion and its transcriptional activity (Figure 1b). None
of them had an effect on HIF-2a (Figure 1b). Of these
genes, CEBPD had the most pronounced effect on HIF-1a
expression, which we investigated further (Figure 1c).
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Figure 1 | The identification of hypoxia-inducible factor (HIF)-1-regulating genes. (a) Scheme of short hairpin RNA (shRNA) library
screening. (b) HeLa cells transfected with small interfering RNA (siRNA) against the five candidate genes, CCAAT/enhancer-binding protein d
(CEBPD), transforming growth factor-beta-induced factor (TGIF), nuclear receptor superfamily 4A member 1 (NR4A1), paired mesoderm homeobox
protein 2A (PHOX2A), or P300/CBP-associated factor (PCAF), were treated under hypoxia for 16h to confirm the shRNA study results. The cells were
processed for immunoblot analysis of HIF-1a and HIF-2a. Four genes except for PHOX2A showed a reduction in HIF-1a protein expression under
hypoxia. The data are representative of three independent experiments, shown in duplicate. (c) Immunoblot analyses of HIF-1a (left panel) and
HREluc activity (right panel) are shown representatively for siRNA-mediated CEBPD knockdown in HeLa cells. Knockdown of CEBPD decreased HIF-
1a and hypoxic induction of HREluc activity in HeLa cells. (right panel) The ratio of luciferase reporter activity (firefly/TK-Renilla) to that of control
siRNA under normoxia is indicated. Bar graph (mean±s.e.m. from three independent experiments) statistics performed using two-way analysis of
variance (ANOVA) with Bonferroni post-hoc tests. *Po0.05. RAS, renal artery stenosis.
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Enhanced CEBPD expression in tubular epithelial cells of
acute and chronic hypoxic injury
CEBPD is a member of the highly conserved C/EBP family
of basic region leucine zipper transcription factors. Although
its basic expression level is low in most normal tissues and
cells, CEBPD is rapidly upregulated by a variety of stimuli,
including inflammatory signals.20,21 We investigated whether
CEBPD expression in vivo correlates with hypoxia in
the kidney. Rodent kidneys were subjected to a series of
hypoxic stimuli and tested for CEPBD expression. CEBPD
was induced in kidneys exposed to systemic hypoxia (8% O2,
6 h), as well as in models of kidney injuries (ischemia–
reperfusion (I/R) injury, cisplatin nephrotoxicity, RAS, and
5/6 nephrectomy (remnant kidney (RK)); Figure 2a and b).
Although the pathogenesis of these models is multifactorial,
they serve as models of acute and chronic ischemic kidney
injury. Cisplatin nephrotoxicity is hypoxic in its outer
medulla because of the reduced blood flow caused by the
toxin,10 and activation of the renin–angiotensin system
results in decreased peritubular capillary flow with subse-
quent hypoxia in RK.22
Immunofluorescence studies of kidney sections using anti-
CEBPD antibody and Phaseolus vulgaris Erythroagglutinin
(PHA-E), a cell-specific marker for proximal tubular cells,
demonstrated that in the control kidney CEBPD was most
evidently expressed in the S3 segment of proximal tubules in
the outer stripe of the outer medulla, physiologically hypoxic
and the most susceptible portion of kidney to hypoxia
(Figure 2c).7 Upon hypoxic stimulation, CEBPD was robustly
induced predominantly in the nuclei of proximal tubular cells
(Figure 2d). CEBPD co-localized with PHA-E in the hypoxic
models and did not co-localize with Tamm–Horsfall protein
(THP, a marker for thick ascending limbs) or with calcium-
binding protein (CaBP, a marker for ascending limb or distal
tubules; data not shown). These data demonstrate that
CEBPD is induced by hypoxia predominantly in proximal
tubular cells.
Hypoxia increases CEBPD expression via HIF-1-independent
pathway and regulates HIF-1a expression in human proximal
tubular cells
CEBPD induction in proximal tubules following a series
of hypoxic injury conditions prompted us to investigate
whether these events occur in a cell-autonomous manner. In
HK-2 cells, hypoxia increased CEBPD expression (Figure 3a).
CEBPD mRNA expression was increased by threefold, which
was not blunted by HIF-1a siRNA (Supplementary Figure
S2A online). This suggested that the hypoxic induction of
CEBPD was mediated independently of HIF-1. Conversely,
CEBPD knockdown by siRNA resulted in reduced HIF-1a
protein expression under hypoxia (Figure 3b), which was
accompanied by a subsequent reduction in HIF transcrip-
tional activity (Figure 3c) and reduced expression of the
endogenous HIF-1 target genes glucose transporter 1
(GLUT1) and VEGF (Figure 3d). We further investigated
whether other members of the C/EBP family might similarly
regulate HIF-1. CCAAT/enhancer-binding protein b (CEBPB),
a known homologue to CEBPD, was not induced by hypoxia
nor did it regulate HIF-1a expression (Supplementary Figure
S2B online). In contrast, CEBPD overexpression significantly
increased HIF-1a protein levels (Supplementary Figure S2C
online). Interestingly, HIF-1a protein upregulation by CEBPD
overexpression was more pronounced in 1% hypoxia but was
evident at near anoxic conditions (0.1% hypoxia). These data
collectively demonstrate that CEBPD regulates endogenous
HIF-1 in tubular cells, which is consistent with previous report
in cancer cell line,23 and this effect is strictly retained within
the context of the CEBPD–HIF-1 axis.
Cross-talk of inflammation and hypoxia in kidney
CEBPD is an inflammatory response gene, which contributes
to both the stimulation and the resolution of inflamma-
tion.20,24 CEBPD is induced by bacterial lipopolysaccharide
(LPS), interferon-g, interleukin (IL)-1b, tumor necrosis
factor (TNF)-a, and IL-6 in myeloid cells.24–26 On the
other hand, HIF-1a is induced under normoxic condition
by LPS, growth factors such as epidermal growth factor
or insulin, and inflammatory cytokines such as IL-1b
or TNF-a,27–29 depending on the cell type, as well as the
pathophysiologial contexts.
These facts led us to hypothesize that tissue inflammation
might fine-tune HIF-1 through CEBPD expression. In
the kidney, inflammation is mediated by resident tubular
cells and inflammatory cells, most commonly by macro-
phages.30,31 Macrophages are present in the tubulointer-
stitium of all of the above-indicated hypoxic kidney
models (Figure 4a). Macrophages and tubular cells under
inflammatory conditions produce various cytokines and
chemokines, including IL-1b, TNF-a, and monocyte
chemotactic protein-1. These were confirmed in all the above
hypoxic kidney models by real-time quantitative (q)RT-PCR
of the diseased renal cortex (Figure 4b). Endogenous HIF-1
target genes, including ANPLT4 (angiopoietin-like 4), VEGF,
SOD1 (superoxidase dismutase 1), and HO-1 (hemeoxygen-
ase-1), were overall upregulated except for the RK model, in
which the insufficient expression of HIF-target genes is
reported (Figure 4b).32 This confirmed that inflammation
and hypoxia coexist and may have interactions in kidney
diseases.
CEBPD regulates HIF-1 in human tubular cells under
inflammatory stimuli
HK-2 cells were accordingly treated with various inflam-
matory stimuli, including LPS, TNF-a, and IL-1b (Supple-
mentary Figure S3A and B online, Figure 5a and b). Whereas
neither LPS nor TNF-a influenced the expression of CEBPD
or HIF-1a (Supplementary Figures 3A and B online), IL-1b
induced CEBPD and HIF-1a protein expression in a dose-
and time-dependent manner under normoxia (Figure 5a
and b). The parallel measurement of IL-6 or monocyte
chemotactic protein-1 confirmed the efficacy of each
treatment (Supplementary Figure S3A online, Figure 5a). A
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time-lapse study revealed that the induction of CEBPD
preceded that of HIF-1a (Figure 5b), suggesting the existence
of a CEBPD/HIF-1 pathway; indeed, HIF-1a induction by
IL-1b was shown to be CEBPD dependent through siRNA
knockdown and overexpression experiments (Figure 5c and
Supplementary Figure S3C online). This regulation was also
observed in A549 cells, a human lung carcinoma cell line
(data not shown). These results indicate that CEBPD
regulates the expression of HIF-1a protein not only under
hypoxia but also under inflammatory conditions.
CEBPD regulates HIF-1a at the transcriptional level
HIF-a expression is tightly regulated at multiple steps. While
the posttranslational ubiquitination subsequent to oxygen-
dependent hydroxylation by PHD is the dominant step,16 the
quantity of HIF-a is also influenced through changes in the
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Figure 2 | CCAAT/enhancer-binding protein d (CEBPD) is expressed in hypoxic kidney tubular cells in vivo. (a) Mice were exposed
to 8% O2 for 6 h using a hypoxia chamber (hypoxia group, n¼ 6). The mice at ambient oxygen were used as the control (control group, n¼ 5).
The whole kidney was examined for CEBPD expression by real-time quantitative (q)RT-PCR. (b) The CEBPD expression levels in the renal cortex
of acute and chronic rat hypoxic injuries were evaluated by qRT–PCR. (A) The ischemia–reperfusion (I/R) group (control group, n¼ 6; I/R group,
n¼ 6). (B) The cisplatin nephrotoxicity group (control group, n¼ 6; cisplatin group, n¼ 7). (C) The remnant kidney (RK) group (control group,
n¼ 5; RK-1w group, n¼ 5; RK-4w group, n¼ 5). (D) The RAS group (control group, n¼ 6; RAS group, n¼ 6). (c) Fluorescent images of control
kidney tissues for CEBPD and Phaseolus vulgaris Erythroagglutinin (PHA-E), a marker for proximal tubules. (A–C) Cortex and (D–F) outer stripe
(OS) of the outer medulla, 200. Bar¼ 50 mm. CEBPD is stained in the S3 segment of proximal tubules in the OS. (G) Cortex and (H) OS of the
outer medulla for further higher magnification, 400. Bar¼ 30 mm. (d) (A) Control kidney and four hypoxic kidney models ((B) I/R group, (C)
cisplatin group, (D) RK group, and (E) RAS group) were stained with an anti-CEBPD antibody. CEBPD is stained in the nuclei of tubular cells in all
four models compared with the control kidney. Original magnifications, 400. Bar¼ 30mm. Bar graph (combined results from two independent
experiments, shown as mean±s.d.) statistics performed using Student’s t-test or one-way analysis of variance (ANOVA) with Dunnett’s post-hoc
tests. *Po0.05 and **Po0.01.
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transcriptional and translational rates, particularly in tumor
and inflammatory cells.18 Because CEBPD regulated HIF-1a
expression under various O2 concentrations, including
those under which the PHD activity is already severely
impaired, we hypothesized that the latter mechanisms may be
involved in the control of HIF-1a by CEBPD. In HK-2
cells, treatment with actinomycin, a transcription inhibitor,
decreased HIF-1a expression under hypoxia or IL-1b
treatment (Figure 6a). HIF-1a mRNA showed a CEBPD-
dependent increase under both conditions (Figure 6b).
Cycloheximide, a protein synthesis inhibitor, did not show
differences in HIF-1a protein half-lives between control
and CEBPD siRNA groups, whereas MG132, a proteasome
inhibitor, clearly demonstrated a decrease in the HIF-1a
synthesis in the CEBPD siRNA group (Supplementary
Figure S4A and B online), which indicated that CEBPD
regulates HIF-1a at the transcription or the trans-
lation level. This was also confirmed by an experiment using
a 2-oxoglutarate analog, DMOG, which disallows PHD
enzymatic activity and thus prevents HIF-a degradation
(Supplementary Figure S4C online). Furthermore, PI3K/AKT
or mammalian target of rapamycin signaling has been
implicated in the transcriptional or translational regulation
of HIF-1a in several tumor cells. However, pretreatment
with specific inhibitors, PI3K inhibitor (LY294002) and
rapamycin, had no effect on the expression of HIF-1a,
suggesting that these pathways were not involved in our study
(Supplementary Figure S4D online).27,29,33
These results altogether indicated that HIF-1a expression
levels under these conditions were regulated at the transcrip-
tional and/or the translational level. Consistently, the activity
of 1.3k human HIF-1a promoter was dependent on CEBPD
(Figure 6c). siRNA knockdown of CEBPD significantly
decreased HIF-1a promoter activity.
The HIF-1a promoter contains six potential binding
motifs for C/EBP (motif 1–4) within its 1.3-kb region
(Figure 6c);21,34 therefore, we tested for potential binding
of CEBPD to the promoter. Because a pilot transfection of
the minimal promoter in close proximity to the HIF-1a
transcriptional start site did not reveal significant changes
following CEBPD stimulation (data not shown), we specu-
lated that the potential CEBPD binding sites might be one
(or more) of the five C/EBP motifs indicated in Figure 6c.
Mutations were introduced against each of the candidate
C/EBP motifs, and the mutant promoters were tested for
the CEBPD response. A mutation at the  227/ 222 bp
site cancelled the CEBPD-dependent increase in promoter
activity (Figure 6d). Chromatin immunoprecipitation (ChIP)
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Figure 3 | Hypoxia-inducible factor (HIF)-1 regulation by CCAAT/enhancer-binding protein d (CEBPD) in tubular epithelial cells.
(a) CEBPD protein is upregulated by hypoxia (0.1% O2) in HK-2 cells. (b) Knockdown of CEBPD decreased HIF-1a protein expression. Right panel
shows densitometrical quantification of HIF-1a protein under hypoxic condition of three independent experiments. (c) Knockdown of CEBPD
significantly decreased HREluc activity under hypoxia. The ratio of luciferase reporter activity (firefly/CMV-Renilla) to that of control small
interfering RNA (siRNA) under normoxia is indicated. (d) Real-time qRT-PCR for HIF-1 target genes, glucose transporter 1 (GLUT1) and vascular
endothelial growth factor (VEGF), also demonstrated that their induction under hypoxia is dependent on CEBPD. Bar graph (mean±s.e.m. or
representative of three independent experiments) statistics performed using two-way analysis of variance (ANOVA) with Bonferroni post-hoc
tests. *Po0.05 and **Po0.01.
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–PCR analysis confirmed CEBPD recruitment to this HIF-1a
promoter ( 227/ 222 bp) under hypoxia or IL-1b treat-
ment (Figure 6e). Collectively, these results indicate that
CEBPD binds to the HIF-1a promoter and transcriptionally
upregulates its expression in response to hypoxia or
inflammatory stimulation.
The NF-jB pathway is involved in CEBPD activation under
hypoxic or inflammatory stimuli
The expression levels of both CEBPD and HIF-1a
are regulated by NF-kB signaling in certain cell types,
although the detailed pathways of the latter remain largely
unknown.19,35 In HK-2 cells, NF-kB activity was increased by
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hypoxia (Figure 7a); conversely, siRNA knockdown of p65, a
component of NF-kB, led to a decrease in HREluc, indicating
that the HIF activity was partially mediated by NF-kB
(Figure 7b). On the basis of our previous observation that
CEBPD augments HIF-1a expression in hypoxia and allows
its normoxic, IL-1b-dependent accumulation, we hypo-
thesized that NF-kB signaling might underlie hypoxic- or
IL-1b-stimulated CEBPD expression, which is responsible for
the induction of HIF-1a. Upon NF-kB inhibition by the IkB-
a phosphorylation and degradation inhibitor (BAY11-7082)
or p65 siRNA, the expression levels of both CEBPD and
HIF-1a significantly decreased (Figure 7c). Conversely, stable
CEBPD overexpression partially rescued the reduced HIF-1a
expression caused by NF-kB inhibition (Figure 7d). In
summary, these results signify a novel NF-kB/CEBPD/HIF-1
pathway in which CEBPD was primarily responsible for the
NF-kB-mediated fine-tuning of HIF-1a (Figure 7e).
DISCUSSION
In this study, we identified novel regulators of HIF-1a
expression in kidney using shRNA library screening. Out of
the four identified genes, CEBPD had the most striking effect,
which was induced by hypoxia or inflammation in tubular
epithelial cells via HIF-1-independent, NF-kB-dependent
pathways, and CEBPD regulated HIF-1a expression through
transcriptional upregulation.
CEBPD is a transcription factor originally identified as an
inflammatory response gene.24,25 Although a small amount
of mRNA is observed in the lung, adipose tissue, and
intestine, its expression is generally low in the majority of
normal tissues, including the kidney.36,37 CEBPD is involved
in a wide range of cell type–specific processes, such as
differentiation and proliferation, thus contributing to various
physiological and pathological conditions. CEBPD deficiency
causes genomic instability in mouse embryo fibroblasts,38
and CEBPD is a tumor-suppressor gene in breast, cervical,
and liver cancers.33 With regard to the kidney, CEBPD is
upregulated after LPS stimulation.24 However, its functional
role in renal pathophysiology is largely unknown. Here, we
found that CEBPD was expressed in hypoxic proximal
tubular cells and augmented HIF-1a expression.
The role of CEBPD on HIF-1 regulation was not restricted
to hypoxic settings. We demonstrated that CEBPD also
regulated HIF-1a under normoxic conditions by inflamma-
tory stimuli. As C/EBP family members have important roles
in inflammation by regulating the functions of both
cytokine-producing inflammatory cells and parenchymal
cells, CEBPD-mediated, O2-independent HIF-1 induction
under inflammation is expected to have an important role in
kidney disease. This regulatory pathway appeared to be
common to other types of parenchymal cells to some extent
because similar results were obtained in other cell lines, such
as A549 lung cancer cells.
There is a growing body of evidence that hypoxia and
inflammation coexist and have interactive roles in various
tissues.39,40 Hypoxia promotes inflammation by increasing
vascular permeability and facilitating production of inflam-
matory mediators by recruited leukocytes or resident paren-
chymal cells. Conversely, inflamed tissues often become
severely hypoxic because of an increase in the metabolic
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demands of cells and a reduction in metabolic substrates.
Thus it is not surprising that HIF-1a activation is also
achieved by growth factors and cytokines. The functional role
of HIF-1 in an inflammatory milieu is best exemplified
in the protection of mucosal barrier in a hapten-based
murine colitis model.41 Furthermore, in myeloid cells, HIF-1
is essential in differentiation and functions even under
normoxia. HIF-1a depletion in these cells results in the
impairment of cell aggregation, motility, invasiveness, and
bacterial killing.42
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Clearly, the importance of HIF within the context of
inflammation also applies to kidney diseases. In experimental
CKD, HIF activation by cobalt chloride reduced macrophage
infiltration in the RK and Thy-1 nephritis models.10,11
Conditional knockout of HIF-1a/2a in myeloid cells
showed more severe inflammation in the unilateral ureteral
obstruction model in mice, and conversely HIF activation by
myeloid-specific Vhl-knockout suppressed inflammation and
fibrosis.43 These interactions of structural cells (e.g., epithelial
cells, endothelial cells, and fibroblasts), inflammatory
cells (e.g., macrophages, dendritic cells, and leukocytes),
and soluble mediators (e.g., growth factors, cytokines, and
chemokines) coordinate in the progression of and resolution
of kidney injury. However, the signaling pathways that
regulate this cross-talk warrant further investigation. On the
basis of our results and the close associations between
macrophages and tubular epithelial cells, we propose that
CEBPD may provide a mechanistic link between inflam-
mation and hypoxia signaling through HIF-1, which possibly
underlies a substantially broader spectrum of pathophysio-
logical contexts, including renal pathophysiology, than
previously thought. In this regard, whether CEBPD activa-
tion provides an additional mode of protection in ischemic
kidney diseases requires further in vivo investigation. In
previous studies, systemic activations of HIFs by cobalt
chloride, PHD inhibitors, inhibiting Factor Inhibiting HIF,
or gene transfer of constitutively active HIF (HIF/VP16)
protected kidney against its injury,8–15 which signified that
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HIF-1 activation was not optimal in diseased kidney. In the
present study, lack of methods to modulate CEBPD activity
in vivo hindered us from validating the hypothesis that
further manipulation to increase the CEBPD activity would
ameliorate CKD progression through HIF-1. Alternatively, it
is also possible that factors other than CEBPD insufficiency––
for example, indoxyl sulfate effect on HIF-1 transcriptional
activity in RK model32––may contribute to the incommen-
surate HIF-1 activity in diseased models. It is also reported
that adipose-derived stem cells derived from end-stage
kidney disease patients show impaired HIF and angiogenic
response, because of weakened expression of PCAF.44 Further
studies are needed to fully elucidate the regulating
mechanism of HIF-1 expression and its activity, which are
determined by multiple factors that vary among different
kidney diseases. In our study, the CEBPD/HIF-1 pathway is
activated in various time point from several hours to several
weeks, by either hypoxic or inflammatory stimuli. In this
regard, it remains an open question how long this pathway
persists, and whether there is ever diminishing signal for this
pathway. CEBPD promoter is known to undergo methylation
and becomes silenced in cancer tissues.45,46 These epigenetic
modifications may also have roles in the regulation of
CEBPD in kidney.
We further found that CEBPD regulated HIF-1a at the
transcription level by mechanistically binding to its promo-
ter. In inflammation, LPS or reactive oxygen species have
also been reported to increase HIF-1a mRNA expression
through activating a NF-kB-binding site in the HIF-1a gene
promoter.35,47,48 In agreement with these reports in macro-
phages, we demonstrated that the induction of CEBPD by
hypoxia or IL-1b, and subsequent expression of HIF-1a,
required NF-kB activity. In addition, CEBPD overexpression
partially rescued HIF-1a protein synthesis under NF-kB
inhibition, indicating that CEBPD was the key regulator of
HIF-1a downstream of NF-kB. Interestingly, the NF-kB
binding site ( 197/ 188 bp)48 is adjacent to the respon-
sible CEBPD binding site ( 227/ 222 bp) in the HIF-1a
promoter. In this regard, it remains an open question
whether these two elements synergistically function to
increase HIF-1a transcription. Indeed, C/EBP members
have been reported to physically and functionally interact
with transcription factors other than the bZIP proteins.49–51
The interaction of CEBPD with NF-kB has also been
reported,52,53 and this may account for the mechanism of
stimulus-specific transcriptional responses, as observed in
IL-1b stimulation.
In conclusion, we have discovered the CEBPD-HIF-1
pathway as a new HIF-1-regulating fundamental mechanism
in tubular epithelial cells for the cellular protection against
kidney injury. The data also point to an important role for
NF-kB in this process and provide a potential link between
hypoxia and inflammation through the cross-talk of macro-
phages and tubular cells, which in particular provide insights
into how the tubular environment in the kidney is
maintained under pathophysiological conditions. The results
of our present study advance our understanding of the HIF-1
response in the kidney and may open up possibilities to
control various aspects of the hypoxic response by experi-
mentally manipulating CEBPD/HIF-1 signaling.
METHODS
Cell culture
HK-2, a human proximal tubular cell line, was cultured in
Dulbecco’s modified Eagle’s medium/F-12 (Nissui, Tokyo, Japan)
supplemented with 10% fetal calf serum. HeLa cervical cancer cells
and A549 lung cancer cells were maintained in Dulbecco’s modified
Eagle’s medium (Nissui) containing 10% fetal calf serum. 0.1% O2
stimulation was induced with an anaerobic bag (Anaerocult A
sachets, Merck Chemicals, Darmstadt, Germany). 1% O2 stimula-
tion was accomplished by exposing cells to 1% O2/5% CO2, with the
balance as nitrogen, in a multigas incubator, APM-30D (ASTEC,
Fukuoka, Japan).
Reagents
LPS (E Coli 0111:B4, L3012), actinomycin, MG132, cycloheximide,
and BAY11-7082 were purchased from Sigma (Sigma-Aldrich,
St. Louis, MO). LY294002, human angiotensin II, and rapamycin
were purchased from Calbiochem (Calbiochem, Gibbstown, NJ).
Recombinant human IL-1b (Roche, Basel, Switzerland), DMOG
(Cayman Chemical, Ann Arbor, MI), and recombinant human
TNF-a (R&D Systems, Minneapolis, MN) were used.
Luciferase reporter assay
The HIF-1 transcriptional activity was measured using dual-
luciferase reporter assays (Promega, Madison, WI) in 24-well
culture dishes. 500 ng pGL3 (Promega) vector driven by 7
hypoxia-responsive elements (pHREluc)9 and 25 ng Renilla
luciferase vector (pRL-CMV, pRL-TK, or pRL-SV40) were co-
transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA);
24 h later, the cells were exposed to hypoxia (1% or 0.1%) for 16 h.
The cells were processed for the dual-luciferase assay in fixed protein
aliquots, and HREluc activity was measured using a Lumat 9507
luminometer (EG and Berthold, Bad Wildbad, Germany). The
relative light unit value of the firefly luciferase was divided by that of
the Renilla luciferase to correct for the transfection efficiency. To
measure the HIF-1a promoter activity, a similar method as above
was used. The human 1.3-kb HIF-1a promoter (hHIF-1a1.3K
promoter) fragment was PCR amplified from human genomic DNA
using PrimeStar HS DNA polymerase (Takara Bio, Shiga, Japan)
and primers with SacI or NheI overhangs. Digested and purified
fragments were inserted into the pGL3basic reporter vector
(Promega). Mutations of the potential C/EBP-binding sites
(screened by TRANSFAC, indicated in Figure 6) of the hHIF-
1a1.3k promoter were introduced through PCR. The PCR primers
are listed in Table 1. NF-kB reporter activity was measured using
pNF-kappaB RE-TK hRluc (F) (RIKEN BIOResource Center,
Tsukuba, Japan), and pRL-TK was used as control. The transfection
efficacy was corrected to the pGL3-basic vector.
Plasmids and transient or stable overexpression
For transient overexpression studies, cDNA encoding human
CEBPB or CEBPD was amplified from HK-2 cells using the primers
listed in Table 1 and subcloned into the pMD20-T vector (Takara
Bio). Each fragment was then subcloned into pcDNA3.1 ( )
(Promega). For CEBPB/CEBPD double transfections, each vector
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amount was reduced to half the dose of single vector transfection
(5 mg each, making total 10 mg vector/dish). HK-2 clones, which
stably overexpress CEBPD, were generated through retrovirus
transduction (Platinum Retrovirus Expression System, Pantropic,
Cell Biolabs, San Diego, CA). The above CEBPD in the pMD20-T
vector was further subcloned into the retroviral vector, pMXs-IRES-
Puro, using the XhoI-SnaBI site. The plasmids were transfected to
the packaging cell line, and, the culture supernatants were collected
24 and 48 h later, passed through 0.22-mm filters, and added to the
cells. Drug selection by 4 mg/ml puromycin was initiated 72 h after
infection.
shRNA library screening
The shRNA library screening was performed using essentially the
same method as in our previous work.54 The shRNA expression
plasmid library was constructed against the top 150 continuously
upregulated genes at days 3 and 7 in the RAS model, based on the
pcPUR hU6 vector (Tsukuba, Ibaraki, Japan), which contained a
human U6 promoter, a puromycin resistance gene, and BspMI
cloning sites. Two shRNA vectors were used against each gene.
For the initial screening, the shRNA plasmid, the pHRE-luc vector,
and the pRL-CMV vector were transfected into HeLa cells using
Lipofectamine 2000 according to the manufacturer’s instructions.
Forty-eight hours after transfection, the cells were cultured in 1%
hypoxic conditions for 16 h and evaluated for HRE reporter activity.
The pcPUR hU6 vector containing a targeted sequence against the
HIF-1a gene and 7 tandem thymidine repeats (T7) served as
positive control and negative control, respectively. A clone fulfilling
the following two criteria in two independent experiments was
considered a hit clone: (1) its HREluc activity change was within the
range of 50% compared with positive control; and (2) its HREluc
activity ratio (1% O2/21% O2) was within the range of 50%
Table 1 | A list of primers used in this study
Gene Use Species F/R Sequence (50-30)
CEBPD RT–PCR Human Forward GAAGAGCGCCGGCAAGAGGG
Reverse CGGCGATGTTGTTGCGCTCG
CEBPD RT–PCR Rat Forward GAATTGCTACAGTTTCTTGG
Reverse ATGCGCAGTCTCTTCCTC
CEBPD RT–PCR Mouse Forward TCGACTTCAGCGCCTACATTGACT
Reverse CCGCTTTGTGGTTGCTGTTGAAGA
HIF-1a RT–PCR Human Forward CCATTAGAAAGCAGTTCCGC
Reverse TGGGTAGGAGATGGAGATGC
GLUT1 RT–PCR Human Forward CTTCACTGTCGTGTCGCTGT
Reverse CCAGGACCCACTTCAAAGAA
VEGF RT–PCR Human Forward TCTGAGCAAGGCCCACAGGGA
Reverse CCCTGATGAGATCGAGTACATCTT
IL-6 RT–PCR Human Forward AGTTCCTGCAGAAAAAGGCA
Reverse AAAGCTGCGCAGAATGAGAT
MCP-1 RT–PCR human Forward CCCCAGTCACCTGCTGTTAT
Reverse AGATCTCCTTGGCCACAATG
IL-1b RT–PCR Rat Forward CACCTCTCAAGCAGAGCACAG
Reverse GGGTTCCATGGTGAAGTCAAC
HIF-1a ChIP–PCR Human Forward TCTCCTTTCTCTTTCCTCCG
Reverse GGTTCCTCGAGATCCAATG
IL-6 ChIP–PCR Human Forward TTTCCCCCTAGTTGTGTCTT
Reverse AATCTTTGTTGGAGGGTGAG
HBB ChIP–PCR Human Forward GGGCTGAGGGTTTGAAGTCC
Reverse CATGGTGTCTGTTTGAGGTTGC
CEBPD Vector Human Forward CAGCTCGAGGTGACAGCCTCGCTTGGA
Reverse CGTACGTATGGGTCGTTGCTGAGTCTCT
CEBPB Vector Human Forward CAGCTCGAGAAACTTTAGCGAGTCAGAG
Reverse CGTACGTAAAATTACCGACGGGCTCCC
hHIF-1a1.3K Reporter assay Human Forward GCGAGCTCACACCTCTGAGTAGCTGGA
Reverse GCGCTAGCTACCGAGCTGCAGCTCATT
hHIF-1a1.3K (mut-1222) Reporter assay Human Forward GTAGGTCTACTGAACGTTTAAAAAGAGGTG
Reverse CACCTCTTTTTAAACGTTCAGTAGACCTAC
hHIF-1a1.3K (mut-871) Reporter assay human Forward CTCTTTCCCTGAAAACGTTTTATATGCTTA
Reverse TAAGCATATAAAACGTTTTCAGGGAAAGAG
hHIF-1a1.3K (mut-837) Reporter assay Human Forward TTAACATAGTTTCAGATTTTAAGAT
Reverse GGTATAAATGACTTTAATAAGCATA
hHIF-1a1.3K (mut-629) Reporter assay Human Forward AAAGACCCCGTTGTAACACATCTG
Reverse ACCTAACCATGGGTCAATGTCACC
hHIF-1a1.3K (mut-227) Reporter assay Human Forward GCTGACCGCCTCCTGGTACCCTGAGAGCGG
Reverse CCGCTCTCAGGGTACCAGGAGGCGGTCAGC
HIF-1a siRNA Human Forward AUAUGAUUGUGUCUCCAGCGGCUGG
Reverse CCAGCCGCUGGAGACACAAUCAUAU
Negative control siRNA Human Forward GUACCGCACGUCAUUCGUAUC
Reverse UACGAAUGACGUGCGGUACG
Abbreviations: CEBPD, CCAAT/enhancer-binding protein d; ChIP–PCR, chromatin immunoprecipitation–PCR; GLUT1, glucose transporter 1; HIF-1a, hypoxia-inducible factor 1a;
IL, interleukin; MCP-1, monocyte chemotactic protein-1; RT–PCR, reverse transcriptase–PCR; siRNA, small interfering RNA; VEGF, vascular endothelial growth factor.
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compared with positive control. The hit clones in the first screening
proceeded to the second screening. HeLa cells stably expressing
candidate shRNA plasmids were used. The shRNA plasmids were
transfected into HeLa cells using Lipofectamine 2000. Drug selection
with 1 mg/ml puromycin was initiated after 48 h. The selected cells
in bulk were then cultured in 1% O2 condition for 16 h and
assessed for HIF-1a protein levels through immunoblotting, and
supernatant VEGF levels were assessed using enzyme-linked
immunosorbent assay (ELISA) (R&D Systems). For HREluc
measurements, the pHRE-luc vector and the pRL-CMV vector
were further transfected into these HeLa cells and treated as
described above. These three measurements were then scored
together for the degree of HIF-1 regulation.
siRNA transfection
Control siRNA (Sigma-Aldrich), p65 siRNA (SASI_Hs01_00171091,
Sigma-Aldrich), HIF-1a siRNA (Invitrogen), CEBPD siRNA
(L-010453-00, Thermo Fischer Scientific, Waltham, MA), and
CEBPB siRNA (L-006423-00, Thermo Fischer Scientific) were used
for the siRNA experiments. The target siRNA sequences are listed in
Table 1. HeLa or HK-2 cells were transfected with 5 nM siRNA using
Lipofectamine 2000 according to the manufacturer’s instruction.
After 24 or 48 h, the siRNA-treated cells were processed for further
experiments.
Real-time qRT–PCR
Real-time qRT–PCR assays were performed as previously
described.32,55 The data were calibrated to the b-actin value.
The corresponding primers are described in the literature and
Table 1.
Immunoblotting analysis
The cells were collected for immunoblotting analysis as previously
described.32,55 The primary antibodies were as follows: anti-HIF1a
(Novus Biologicals, Littleton, CO); anti-CEBPD (Santa Cruz Bio-
technology, Santa Cruz, CA); anti-CEBPB (Santa Cruz Biotechno-
logy); anti-p65 (Santa Cruz Biotechnology); anti-phospho-Akt
(Ser473) (Cell Signaling Technology, Danvers, MA); anti-phospho-
p70 S6 kinase (Thr389) (Cell Signaling Technology); and anti-actin
(Sigma-Aldrich). Horseradish peroxidase–conjugated anti-rabbit
immunoglobulin G (IgG; Bio-Rad Laboratories, Hercules, CA) or
anti-mouse IgG (Bio-Rad Laboratories) antibodies were used
as secondary antibodies. The signals were detected with the ECL
Plus reagent (Thermo Scientific) using the chemiluminescence
protocol.
Chromatin immunoprecipitation
The binding of CEBPD to the HIF-1a (ChIP) promoter was assessed
using the chromatin immunoprecipitation assay. HK-2 cells were
cross-linked for 10min using 1% paraformaldehyde and sonicated
into fragments. The fragmented DNA forming a complex with
CEBPD was immunoprecipitated with an anti-CEBPD rabbit
polyclonal antibody (Santa Cruz Biotechnology) and protein
Sepharose beads (GE Healthcare, Buckinghamshire, UK). The
precipitated DNA was used as a template for PCR reactions with
the primers listed in Table 1. The IL-6 promoter region has known
IL-1b-induced CEBPD-binding site, and this was used as a positive
control.56 HBB is the negative-control primer, which was designed
for the promoter regions of chromosome 2.
In vivo experiments
Male C57BL/6NJc1 mice aged 7 weeks (Nippon Seibutsu Zairyo
Center, Tokyo, Japan) were exposed to 8% hypoxia for 6 h using an
oxygen controller, ProOx110 (BioSpherix, Lacona, NY). The mice
exposed to ambient air were used as controls. The mice were
euthanized, and the kidneys were harvested and stored at  80 1C
for qRT–PCR analysis. Other animal experiments were performed
using male Wistar rats aged 6–8 weeks (Nippon Seibutsu Zairyo
Center) under pentobarbital anesthesia. Sham-control rats received
only laparotomy, except for the cisplatin nephrotoxicity model,
where they received intraperitoneal saline injection. At euthanasia,
the kidneys were harvested, fixed in formalin for immunohisto-
chemical analysis, snap-frozen in OCT (Optimal Cutting Tempera-
ture), or stored at  80 1C for qRT–PCR analysis. For acute hypoxic
kidney models, I/R injury and cisplatin nephrotoxicity models were
adopted. Two distinct models of renal disease, the RAS model and
the RK (5/6 nephrectomy) model, were used for chronic hypoxic
kidney models. The surgical procedures were performed as
previously described.8–11,19 Briefly, for I/R injury, after a midline
abdominal incision and right kidney removal, left renal arteries and
veins were occluded for 45min with microaneurysm clamps. The
body temperature was kept constant at 37 1C during the operation.
Twenty-four hours following clamp release, the rats were
euthanized. Cisplatin nephrotoxicity was created by injecting
6mg/kg cisplatin intraperitoneally, and the rats were euthanized 3
days later. RAS was induced by placing a U-shaped silver clip
(0.23mm internal diameter) around the left renal artery through a
midline abdominal incision. The RK model was constructed in two
steps. One week prior to disease induction, the right kidney was
removed. At day 0, infarction of approximately two-thirds of the left
kidney was accomplished by ligation of the posterior and two
anterior branches of the main renal artery. The rats were euthanized
either at 1 or 4 weeks. All mice and rats were housed in the animal
care facility of the University of Tokyo under standardized
pathogen-free conditions (25 1C, 50% humidity, 12 h light/dark
cycle) with food and water available ad libitum. All experiments
were performed in accordance with the guidelines of the Committee
on Ethical Animal Care and Use at the University of Tokyo Graduate
School of Medicine (M-P10-077).
Histopathology and immunohistochemistry
The kidney tissues were prepared and stained as previously
described.32,55 Briefly, the kidneys were either immersion fixed
in neutralized formalin solutions and embedded in paraffin or
snap-frozen in OCT compound. Periodic acid–Schiff staining was
used for routine histological examination. An indirect immuno-
peroxidase method was used to identify the following antigens:
CEBPD with anti-CEBPD rabbit polyclonal antibody (Santa Cruz
Biotechnology); and monocytes/macrophages with murine
monoclonal IgG1 antibody endothelin-1 (Chemicon, Temecula,
CA). Briefly, sections (3mm) were deparaffinized and brought to
water through graded ethanols. Antigen retrieval was performed by
boiling sections in a microwave in 1mmol/l EDTA, pH 6.0.
Endogenous peroxidase activity was quenched using 3% hydrogen
peroxide; nonspecific protein binding was blocked using 2% normal
horse serum (Sigma-Aldrich), and endogenous biotin activity was
quenched using the Avidin/Biotin Blocking Kit (Vector Laboratories,
Burlingame, CA). After blocking, the tissue sections were incubated
with the indicated primary antibody overnight at 4 1C. The
corresponding biotinylated secondary antibodies anti-rabbit IgG
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(Vector Laboratories) or anti-mouse IgG (Vector Laboratories) were
applied followed by an R.T.U. Vectastain Kit (Vector Laboratories).
The immunoreactive antigens sites were detected with hydrogen
peroxide and diaminobenzidine (Wako, Osaka, Japan). For
immunofluorescent staining, frozen tissue sections (4mm) were
briefly air dried and fixed in 100% methanol. The sections were then
blocked with 2% normal horse serum and incubated with primary
antibodies: anti-CEBPD rabbit polyclonal antibody (Santa Cruz
Biotechnology), biotinylated PHA-E (Vector Laboratories), THP
(Cappel, West Chester, PA), or CaBP28k (Sigma-Aldrich) overnight
at 4 1C. The sections were incubated at room temperature for 40min
with secondary antibodies: Texas Red-conjugated anti-rabbit IgG
(Molecular Probes, Eugene, OR), Alexa488 (Molecular Probes),
fluorescein isothiocyanate–conjugated (FITC) anti-goat IgG
(DAKO, Tokyo, Japan), and FITC anti-mouse IgG (Southern
Biotechnology, Birmingham, AL). The images were captured on a
BZ-9000 fluorescence microscope (Keyence, Osaka, Japan) with the
BZ-analyzer software (Keyence).
Statistical analysis
All data are reported as the means±s.e.m. or the means±s.d. The
data for two groups were analyzed using unpaired Student’s t-test.
The differences among more than two groups were analyzed using a
one-way analysis of variance (ANOVA) with post-Dunnett’s test or
a two-way ANOVA with post-Bonferroni’s test. Differences with a
P-valueo0.05 were considered significant. GraphPad Prism version
5.04 for Windows (GraphPad Software, San Diego, CA) was used for
data analysis.
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